<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03051217</url>
  </required_header>
  <id_info>
    <org_study_id>PS0017</org_study_id>
    <nct_id>NCT03051217</nct_id>
  </id_info>
  <brief_title>A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis</brief_title>
  <official_title>Phase 2/3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy and safety of Certolizumab Pegol
      (CZP) in the treatment of moderate to severe chronic plaque Psoriasis (PSO) in Japanese
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 21, 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects achieving a 75% or higher improvement in Psoriasis Area and Severity Index (PASI) score at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>This Outcome Measure applies to subjects with moderate to severe chronic plaque Psoriasis (PSO).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who achieve a Physician's Global Assessment (PGA) Clear or Almost Clear response (with at least 2-category improvement) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>This Outcome Measure applies to subjects with moderate to severe chronic plaque Psoriasis (PSO).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving a 90% or higher improvement in Psoriasis Area and Severity Index (PASI) score at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>This Outcome Measure applies to subjects with moderate to severe chronic plaque Psoriasis (PSO).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dermatology Life Quality Index (DLQI) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>This Outcome Measure applies to subjects with moderate to severe chronic plaque Psoriasis (PSO).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Itch Numeric Rating Scale at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>This Outcome Measure applies to subjects with moderate to severe chronic plaque Psoriasis (PSO).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Certolizumab Pegol (CZP)</measure>
    <time_frame>Blood samples will be collected at baseline (Week 0) and at Weeks 2, 4, 6, 8, 12, 16, 24, 32, 40, 52, 60.</time_frame>
    <description>Blood samples will be collected at indicated time points to determine the CZP plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Certolizumab Pegol-antibody levels in plasma</measure>
    <time_frame>Blood samples will be collected at baseline (Week 0) and at Weeks 2, 4, 6, 8, 12, 16, 24, 32, 40, 52, 60.</time_frame>
    <description>Blood samples will be collected at indicated time points to determine the anti-CZP-antibody concentration.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Moderate to Severe Psoriasis</condition>
  <condition>Generalized Pustular Psoriasis and Erythrodermic Psoriasis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneous (sc) injection every two weeks (Q2W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CZP 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Certolizumab Pegol subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by Certolizumab Pegol subcutaneous (sc) injection 200 mg every two weeks (Q2W) with PBO administered to maintain the blind, starting at Week 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CZP 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 0.9 % saline
Route of Administration: Subcutaneous use Q2W</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>CZP 200 mg</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certolizumab Pegol</intervention_name>
    <description>Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 200 mg/mL
Route of Administration: Subcutaneous use</description>
    <arm_group_label>CZP 200 mg</arm_group_label>
    <arm_group_label>CZP 400 mg</arm_group_label>
    <other_name>Cimzia</other_name>
    <other_name>CDP870</other_name>
    <other_name>CZP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female, &gt;= 20 years of age.

          -  Institutional Review Board-approved written informed consent form is signed and dated
             by the subject.

          -  Other protocol-defined inclusion criteria may apply.

        For subjects with moderate to severe chronic plaque psoriasis (PSO)

          -  Chronic plaque psoriasis for at least 6 months.

          -  Baseline Psoriasis Activity and Severity Index (PASI) &gt;=12 and Body Surface Area (BSA)
             affected by PSO &gt;=10% and Physician's Global Assessment (PGA) score of 3 or higher.

          -  Candidates for systemic PSO therapy and/or phototherapy and/or chemophototherapy.

        For subjects with generalized pustular PSO or erythrodermic PSO

          -  Diagnosis of generalized pustular PSO or erythrodermic PSO at Screening.

          -  History of plaque-type PSO if subjects have a diagnosis of erythrodermic PSO.

          -  Baseline BSA affected by PSO &gt;=80% if subjects have a diagnosis of erythrodermic PSO.

        Exclusion Criteria:

          -  Female subject who is breastfeeding, pregnant, or plans to become pregnant during the
             study or within 5 months following last dose of study drug. Male subject who is
             planning a partner pregnancy during the study or within 5 months following the last
             dose of study drug.

          -  Subject has guttate psoriasis or drug-induced psoriasis. For subjects with moderate to
             severe plaque psoriasis, erythrodermic or pustular forms of psoriasis also are
             excluded.

          -  History of current, chronic, or recurrent infections of viral, bacterial, or fungal
             origin as described in the protocol. Also, subjects with a high risk of infection in
             the Investigator's opinion.

          -  History of a lymphoproliferative disorder including lymphoma or current signs and
             symptoms suggestive of lymphoproliferative disease.

          -  History of other malignancy or concurrent malignancy as described in the protocol.

          -  Class III or IV congestive heart failure

          -  History of, or suspected, demyelinating disease of the central nervous system (e.g.,
             multiple sclerosis or optic neuritis).

          -  Subject has any other condition which, in the Investigator's judgment, would make the
             subject unsuitable for inclusion in the study.

          -  Concurrent medication restrictions as described in the protocol.

          -  Subject with known tuberculosis (TB) infection, at high risk of acquiring TB
             infection, or with untreated latent tuberculosis infection (LTBI) or current or
             history of nontuberculous mycobacterial (NTMB) infection.

          -  Subject has any protocol defined clinically significant laboratory abnormalities at
             the screening

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>UCB (+1 844 599 2273)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ps0017 024</name>
      <address>
        <city>Asahikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 012</name>
      <address>
        <city>Bunkyo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 010</name>
      <address>
        <city>Chiyoda-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 007</name>
      <address>
        <city>Chūōku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 004</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 039</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 028</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 040</name>
      <address>
        <city>Hamamatsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 013</name>
      <address>
        <city>Itabashi-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 022</name>
      <address>
        <city>Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 032</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 031</name>
      <address>
        <city>Kurume</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 021</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 041</name>
      <address>
        <city>Matsumoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 009</name>
      <address>
        <city>Minatoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 033</name>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 016</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 029</name>
      <address>
        <city>Nankoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 005</name>
      <address>
        <city>Obihiro</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 037</name>
      <address>
        <city>Osaka-Sayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 017</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 042</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 001</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 027</name>
      <address>
        <city>Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 015</name>
      <address>
        <city>Shimotsuke</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 008</name>
      <address>
        <city>Shinagawa-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 003</name>
      <address>
        <city>Shinjuku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 011</name>
      <address>
        <city>Shinjuku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 034</name>
      <address>
        <city>Sumida</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 038</name>
      <address>
        <city>Takaoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 002</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 014</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ps0017 025</name>
      <address>
        <city>Tsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2017</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>PSO</keyword>
  <keyword>Chronic plaque psoriasis</keyword>
  <keyword>Certolizumb Pegol</keyword>
  <keyword>Cimzia</keyword>
  <keyword>Generalized pustular psoriasis and erythrodermic psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

